SEC Company Response from ChronoScale Holdings Corp (CHRN) (CIK 0001549084) (CHRN) — Mar 13, 2014
ChronoScale Holdings Corp (CHRN) (CIK 0001549084)
Date: March 13, 2014 · CIK: 0001549084 · Accession: 0001144204-14-015553
AI Filing Summary & Sentiment
File numbers found in text: 333-181229
Referenced dates: February 19, 2014, March 5, 2014
Letter
Ekso Bionics Holdings, Inc.
Ekso Bionics, Inc.
1414 Harbour Way South
Suite 1201
Richmond, CA 94804
March 13, 2014
VIA EDGAR CORRESPONDENCE
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jay Ingram, Legal Branch Chief
Re: Ekso Bionics Holdings, Inc.Form 8-K
Filed January 23, 2014
File No. 333-181229
Ladies and Gentlemen:
This letter is provided as a supplement to the letter dated March 5, 2014 from Nutter, McClennen & Fish, LLP, counsel to Ekso Bionics Holdings, Inc. (the “Company”), responding to the comments of the staff of the Securities and Exchange Commission (the “Commission”) provided by a letter dated February 19, 2014 related to the Company’s Form 8-K filed January 23, 2014 (the “Form 8-K”). The Company acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the Form 8-K, that staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the Form 8-K, and that the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please feel free to contact the undersigned at (707) 324-9509 if you have any questions relating to the Form 8-K or this letter.
Sincerely,
/s/ Max Scheder-Bieschin
Show Raw Text
CORRESP
1
filename1.htm
Ekso Bionics Holdings, Inc.
Ekso Bionics, Inc.
1414 Harbour Way South
Suite 1201
Richmond, CA 94804
March 13, 2014
VIA EDGAR CORRESPONDENCE
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jay Ingram, Legal Branch Chief
Re: Ekso Bionics Holdings, Inc.Form 8-K
Filed January 23, 2014
File No. 333-181229
Ladies and Gentlemen:
This letter is provided as a supplement
to the letter dated March 5, 2014 from Nutter, McClennen & Fish, LLP, counsel to Ekso Bionics Holdings, Inc. (the “Company”),
responding to the comments of the staff of the Securities and Exchange Commission (the “Commission”) provided
by a letter dated February 19, 2014 related to the Company’s Form 8-K filed January 23, 2014 (the “Form 8-K”).
The Company acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the Form 8-K, that staff comments
or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the
Form 8-K, and that the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any
person under the federal securities laws of the United States.
Please feel free to contact the undersigned
at (707) 324-9509 if you have any questions relating to the Form 8-K or this letter.
Sincerely,
/s/ Max Scheder-Bieschin
Max Scheder-Bieschin
cc:
Kamyar Daneshvar, Securities and Exchange Commission
Nathan Harding, Ekso Bionics Holdings, Inc.
Michelle L. Basil, Nutter, McClennen & Fish, LLP